BDBM790033 2-[(10S,17E)-16-ethoxy-6,8,10-trimethyl- 12-(propan-2-yl)-2,8,10,11,12,13- hexahydro-14H-3,5- ethenotripyrazolo[3,4-f:3',4'-j:4$#8243;,3$#8243;- n][1,4]oxazacyclopentadecin-14- yl]ethan-1-ol::US20250353864, Example 142
SMILES CCOC(=N)C1=C(\NCCO)CN(C(C)C)C[C@H](C)Oc2c(c(C)nn2C)-c2ccc3[nH]nc(c3c2)\C=C\1
InChI Key
Data 11 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 11 hits for monomerid = 790033
Affinity DataIC50: 0.900nMAssay Description:Table 1: The inhibitory activities against EGFR WT, EGFR (D770_N771insNPG), EGFR Δ746-750 mutant, EGFR Δ746-750/C797S mutant, EGFR L858R mutant, EGFR...More data for this Ligand-Target Pair
Affinity DataIC50: 1.11nMAssay Description:Table 1: The inhibitory activities against EGFR WT, EGFR (D770_N771insNPG), EGFR Δ746-750 mutant, EGFR Δ746-750/C797S mutant, EGFR L858R mutant, EGFR...More data for this Ligand-Target Pair
Affinity DataIC50: 1.29nMAssay Description:Table 1: The inhibitory activities against EGFR WT, EGFR (D770_N771insNPG), EGFR Δ746-750 mutant, EGFR Δ746-750/C797S mutant, EGFR L858R mutant, EGFR...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-745,751-1210,C797S](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 1.32nMAssay Description:Table 1: The inhibitory activities against EGFR WT, EGFR (D770_N771insNPG), EGFR Δ746-750 mutant, EGFR Δ746-750/C797S mutant, EGFR L858R mutant, EGFR...More data for this Ligand-Target Pair
Affinity DataIC50: 1.83nMAssay Description:Table 1: The inhibitory activities against EGFR WT, EGFR (D770_N771insNPG), EGFR Δ746-750 mutant, EGFR Δ746-750/C797S mutant, EGFR L858R mutant, EGFR...More data for this Ligand-Target Pair
Affinity DataIC50: 2.14nMAssay Description:Table 1: The inhibitory activities against EGFR WT, EGFR (D770_N771insNPG), EGFR Δ746-750 mutant, EGFR Δ746-750/C797S mutant, EGFR L858R mutant, EGFR...More data for this Ligand-Target Pair
Affinity DataIC50: 5.91nMAssay Description:Table 3: Kinase protein and substrate were pre-diluted in the HEPES assay buffer (100 mM HEPES, pH 7.5, 0.01% Triton X-100, 0.1% BSA, 5 mM MgCl2, 1 m...More data for this Ligand-Target Pair
Affinity DataIC50: 11.9nMAssay Description:Table 3: Kinase protein and substrate were pre-diluted in the HEPES assay buffer (100 mM HEPES, pH 7.5, 0.01% Triton X-100, 0.1% BSA, 5 mM MgCl2, 1 m...More data for this Ligand-Target Pair
Affinity DataIC50: 13.9nMAssay Description:Table 3: Kinase protein and substrate were pre-diluted in the HEPES assay buffer (100 mM HEPES, pH 7.5, 0.01% Triton X-100, 0.1% BSA, 5 mM MgCl2, 1 m...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [1-770,'NPG',771-1210](Human)
Blossomhill Therapeutics
US Patent
Blossomhill Therapeutics
US Patent
Affinity DataIC50: 16.7nMAssay Description:Table 1: The inhibitory activities against EGFR WT, EGFR (D770_N771insNPG), EGFR Δ746-750 mutant, EGFR Δ746-750/C797S mutant, EGFR L858R mutant, EGFR...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+3nMAssay Description:Table 3: Kinase protein and substrate were pre-diluted in the HEPES assay buffer (100 mM HEPES, pH 7.5, 0.01% Triton X-100, 0.1% BSA, 5 mM MgCl2, 1 m...More data for this Ligand-Target Pair